The first patient with small cell lung cancer has been dosed in a trial of peluntamig (PT217) combined with chemotherapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback